ENZYMATICA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.17 SEK | -0.94% |
|
+0.96% | -19.65% |
| Apr. 25 | Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 27 | Enzymatica AB Announces Composition of Nomination Committee | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 60.68 | 325.9 | 144.4 | 71.02 | 64.26 | 51.33 | - | - |
| Enterprise Value (EV) 1 | 58.04 | 323.4 | 141.2 | 66.3 | 65.96 | 53.79 | 49.68 | 53.53 |
| P/E ratio | -14.1 x | -211 x | -29 x | -10.3 x | - | -12.3 x | -21.1 x | -24.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.53 x | 24.4 x | 23.4 x | 15.2 x | 13.2 x | 8.56 x | 4.45 x | 2.69 x |
| EV / Revenue | 9.11 x | 24.2 x | 22.9 x | 14.2 x | 13.5 x | 8.97 x | 4.3 x | 2.81 x |
| EV / EBITDA | -17 x | -561 x | -34.1 x | -11.4 x | - | -14.3 x | -21.7 x | -25.4 x |
| EV / FCF | -14.6 x | -182 x | -31.8 x | -10.1 x | - | -15.5 x | -14.3 x | -14.3 x |
| FCF Yield | -6.85% | -0.55% | -3.15% | -9.94% | - | -6.46% | -7% | -7.01% |
| Price to Book | 4.92 x | 26.7 x | 10.8 x | 5.89 x | - | 8.22 x | 4.78 x | 5.92 x |
| Nbr of stocks (in thousands) | 142,824 | 142,824 | 149,324 | 164,257 | 164,257 | 173,382 | - | - |
| Reference price 2 | 0.4248 | 2.282 | 0.9674 | 0.4324 | 0.3912 | 0.2961 | 0.2961 | 0.2961 |
| Announcement Date | 2/13/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.369 | 13.34 | 6.167 | 4.667 | 4.875 | 5.996 | 11.54 | 19.06 |
| EBITDA 1 | -3.424 | -0.577 | -4.136 | -5.819 | - | -3.752 | -2.288 | -2.105 |
| EBIT 1 | -4.333 | -1.447 | -4.875 | -6.504 | -4.603 | -4.462 | -1.7 | 0.972 |
| Operating Margin | -68.03% | -10.85% | -79.04% | -139.37% | -94.42% | -74.42% | -14.73% | 5.1% |
| Earnings before Tax (EBT) 1 | -4.337 | -1.567 | -4.923 | -6.554 | -4.761 | -4.622 | -1.564 | 1.155 |
| Net income 1 | -4.26 | -1.583 | -4.89 | -6.546 | -4.762 | -4.581 | -1.564 | 1.155 |
| Net margin | -66.88% | -11.87% | -79.3% | -140.27% | -97.69% | -76.41% | -13.54% | 6.06% |
| EPS 2 | -0.0301 | -0.0108 | -0.0334 | -0.0420 | - | -0.0240 | -0.0140 | -0.0120 |
| Free Cash Flow 1 | -3.975 | -1.776 | -4.443 | -6.593 | - | -3.477 | -3.477 | -3.752 |
| FCF margin | -62.41% | -13.31% | -72.05% | -141.29% | - | -57.99% | -30.12% | -19.69% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.019 | 0.4225 | 0.9302 | 1.678 | 1.586 | 1.264 | 0.859 | 1.219 | 1.516 | 0.8652 | 0.789 | 1.999 | 3.264 |
| EBITDA | -0.9519 | -1.678 | -1.412 | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.135 | -1.842 | -1.536 | - | -2.057 | - | -1.093 | -0.8039 | -1.32 | -1.691 | -1.067 | -0.876 | -0.502 |
| Operating Margin | -56.23% | -435.99% | -165.08% | - | -129.69% | - | -127.28% | -65.93% | -87.02% | -195.38% | -135.23% | -43.82% | -15.38% |
| Earnings before Tax (EBT) | -1.151 | -1.839 | -1.519 | - | - | - | - | - | - | - | - | - | - |
| Net income | -1.159 | -1.832 | -1.485 | - | - | - | - | - | - | - | - | - | - |
| Net margin | -57.41% | -433.66% | -159.64% | - | - | - | - | - | - | - | - | - | - |
| EPS | -0.007540 | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/17/22 | 4/28/22 | 7/19/22 | 11/2/22 | 2/17/23 | 4/27/23 | 7/18/23 | 11/7/23 | 2/16/24 | 4/25/24 | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1.7 | 2.46 | - | 2.2 |
| Net Cash position 1 | 2.63 | 2.51 | 3.22 | 4.72 | - | - | 1.65 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.6559 x | - | -1.043 x |
| Free Cash Flow 1 | -3.97 | -1.78 | -4.44 | -6.59 | - | -3.48 | -3.48 | -3.75 |
| ROE (net income / shareholders' equity) | -29.4% | -11.7% | -39.2% | -54.6% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.0900 | 0.0900 | 0.0900 | 0.0700 | - | 0.0400 | 0.0600 | 0.0500 |
| Cash Flow per Share | -0.0300 | - | - | - | - | - | - | - |
| Capex 1 | 0.09 | 0.55 | 0.6 | 0.35 | 0.07 | 0.09 | 0.09 | 0.18 |
| Capex / Sales | 1.41% | 4.16% | 9.77% | 7.59% | 1.43% | 1.53% | 0.8% | 0.96% |
| Announcement Date | 2/13/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/16/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.65% | 51.33M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- ENZY Stock
- Financials Enzymatica AB